Combined General Meeting of August 17, 2022: Onxeo Shareholders Approve Withdrawal From the Nasdaq First North Market in Copenhagen

Rhea-AI Summary

Onxeo S.A. (Euronext Paris: ALONX, Nasdaq First North: ONXEO) plans to delist from Nasdaq First North following shareholder approval at a recent meeting. The Board of Directors has been authorized to execute the delisting, which is expected to be finalized within 10 weeks post-approval by the exchange operator. Danish shareholders will be able to trade their shares on Euronext Growth, maintaining the same ISIN code. No changes will be made to the share capital or rights attached to shares during this transition.

Positive

• Shareholder approval for delisting could streamline operations and focus on Euronext Growth.
• Automatic exchange of securities allows Danish shareholders continued access to trading without losses.

Negative

• Delisting from Nasdaq may reduce visibility and trading volume, impacting liquidity.

Company to submit delisting request to Nasdaq

PARIS--(BUSINESS WIRE)-- Regulatory News:

Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in particular against rare or resistant forms of cancer, today announced that the Combined General Meeting held today has adopted all the resolutions presented in line with the recommendations of the Board of Directors.

In particular, the shareholders approved the delisting of the Company's shares on the Nasdaq First North market in Copenhagen and granted all powers to the Board of Directors to carry out the delisting.

The company will in the coming days formally request and ask for approval of the delisting of the company shares from trading on the Nasdaq First North from the Danish stock exchange operator.

After approval by the market operator the effective delisting of Onxeo shares from the Nasdaq First North market is expected to take place after an additional period of 10 weeks.

The company is contemplating to arrange for the automatic exchange of securities in order that Danish shareholders will be able to trade their Onxeo shares on Euronext Growth, with the same ISIN code (FR0010095596). No change will be made to the number of ordinary shares or to the rights attached to Onxeo shares and the shares will continue to be traded on Euronext Growth Paris. The share capital of the Company will therefore remain unchanged. The company will provide further details when an approval for the delisting has been obtained from Nasdaq First North.

For further information, shareholders are invited to consult the Frequently asked questions relating to the withdrawal of the Company from the Nasdaq First North market in Copenhagen, available on the Company's website, in the General Meetings section. The result of the votes by resolution and the minutes of the meeting will be available there within the legal deadlines. Shareholders may also contact Onxeo’s investors’ relations team by email at investors@onxeo.com.

Next financial press release:

Publication of 2022 half-year results: Tuesday, September 13, 2022 (after market)

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

platON is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

AsiDNA, the first compound from platON, is a highly differentiated, clinical-stage first-in-class candidate in the field of DNA damage response (DDR) applied to oncology. Its decoy and agonist mechanism acting upstream of multiple DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor DNA-damaging agents such as radio-chemotherapy. AsiDNA is currently being studied in Europe in combination with other treatment modalities in difficult-to-treat solid tumors.

OX400 is a series of new drug candidates from platON, designed to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. The lead OX400 candidate is currently being optimized and is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

For further information, please visit www.onxeo.com.

Forward looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company’s registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (www.onxeo.com) and/or the AMF (www.amf-france.org).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005646/en/

Onxeo

Investor Relations

investors@onxeo.com

+33 1 45 58 76 00

Media Relations

Arthur Rouillé

NewCap

onxeo@newcap.eu

+33 1 44 71 94 98

Investor Relations / Strategic Communication

Dušan Orešanský / Emmanuel Huynh

NewCap

onxeo@newcap.eu

+33 1 44 71 94 92

Certified Adviser for Nasdaq First North

Kapital Partner

www.kapitalpartner.dk

info@kapitalpartner.dk

+45 89 88 78 46

Source: Onxeo S.A.

FAQ

What is the upcoming delisting of Onxeo on Nasdaq First North?

Onxeo plans to delist from Nasdaq First North following shareholder approval to focus on Euronext Growth.

When will Onxeo's delisting take effect?

The delisting is expected to take place within 10 weeks after receiving approval from Nasdaq First North.

How will the delisting affect Onxeo shareholders?

Danish shareholders will transition to Euronext Growth while maintaining their shares' ISIN code and rights.

What are Onxeo's plans after the delisting from Nasdaq?

Onxeo aims to streamline its operations and enhance focus on its core market on Euronext Growth.